University of Notre Dame DU Lac raised its position in DBV Technologies SA – (NASDAQ:DBVT) by 94.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,115 shares of the company’s stock after buying an additional 55,860 shares during the quarter. University of Notre Dame DU Lac owned about 0.23% of DBV Technologies worth $2,832,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in shares of DBV Technologies in the third quarter valued at $132,000. Quantbot Technologies LP bought a new stake in shares of DBV Technologies in the third quarter valued at $146,000. Geode Capital Management LLC raised its stake in shares of DBV Technologies by 20.2% in the fourth quarter. Geode Capital Management LLC now owns 20,833 shares of the company’s stock valued at $512,000 after buying an additional 3,499 shares during the period. Alps Advisors Inc. raised its stake in shares of DBV Technologies by 9.1% in the third quarter. Alps Advisors Inc. now owns 47,477 shares of the company’s stock valued at $2,015,000 after buying an additional 3,964 shares during the period. Finally, Dynamic Technology Lab Private Ltd raised its stake in shares of DBV Technologies by 87.6% in the third quarter. Dynamic Technology Lab Private Ltd now owns 11,655 shares of the company’s stock valued at $495,000 after buying an additional 5,441 shares during the period. Hedge funds and other institutional investors own 45.72% of the company’s stock.
DBV Technologies SA – (NASDAQ:DBVT) traded down $0.44 during trading on Wednesday, reaching $22.56. The company had a trading volume of 141,392 shares, compared to its average volume of 335,737. DBV Technologies SA – has a twelve month low of $20.08 and a twelve month high of $50.57.
DBVT has been the topic of several research reports. JMP Securities started coverage on DBV Technologies in a research note on Friday, November 17th. They issued an “outperform” rating on the stock. Zacks Investment Research lowered DBV Technologies from a “hold” rating to a “sell” rating in a research note on Monday, December 25th. BidaskClub lowered DBV Technologies from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. Finally, Citigroup set a $57.00 price objective on DBV Technologies and gave the company a “buy” rating in a research note on Wednesday, February 14th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $49.63.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/14/university-of-notre-dame-du-lac-raises-position-in-dbv-technologies-sa-dbvt.html.
DBV Technologies Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.